About Christopher Anderson, MD

I am a Neurocritical Care physician with research expertise in the medical genetics of complex disease, specifically ischemic and hemorrhagic stroke. I have devoted my research career to leveraging computational, genetic, and epidemiologic tools to define mechanisms underlying cerebrovascular disease, with the ultimate goal of using this information to drive improvement in stroke care through the identification of novel treatment targets and implementation of precision strategies for primary and secondary prevention. I am clinically appointed at Massachusetts General Hospital in the Division of Neurocritical Care and Emergency Neurology, with research appointments at the MGH Center for Genomic Medicine and the Broad Institute. My clinical, research, and leadership activities serve the common goal of providing excellent care to patients with neurologic disease through academics and investigation, education and career development, clinical excellence, and administration and institutional service.

 

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Center for Genomic Medicine
185 Cambridge Street
Simches Research Ctr
Boston, MA 02114
855-644-6387
Fax: 617-724-8769

Medical Education

  • MD,
  • Residency, Brigham and Women's Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Neurology, American Board of Psychiatry and Neurology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

The Anderson laboratory espouses the mission of the MGH Center for Genomic Medicine as it applies to ischemic stroke and intracerebral hemorrhage (ICH). We employ translational and computational techniques to understand how genetic associations can teach us about the pathogenic mechanisms of stroke, and how we can apply genetic associations to guide therapeutic and diagnostic approaches at the bedside. Members of the Anderson lab use population genetics approaches to the study of cerebrovascular disease, with special emphasis on pathway-based and translational genomic techniques that clarify the causal biological mechanisms through which associated genetic variants exert their influence on disease risk and outcome.

Programs within the lab include: 1) Leveraging genetic tools to understand how risk factors influence the development of cerebrovascular disease, 2) Determining the causal mechanisms through which common and rare genetic variants lead to ICH, and 3) Developing precision genomic medicine tools for stratification of genetic risk in individuals at risk for ischemic stroke. Because genetic analyses require both clinical characteristics as well as genotypic information, members of the lab cultivate expertise in multiple clinical, imaging, and computational domains. Fellows, coordinators, and students in the lab devote their efforts to projects across these disciplines, including clinical contact with stroke survivors for determination of outcomes, ascertainment of qualitative and quantitative imaging phenotypes for genetic and epidemiologic studies, and application of advanced bioinformatic tools for interpretation and analysis of genetic and genomic data. All of these enterprises serve the common goal of improving our understanding of cerebrovascular disease, so that we may develop new approaches to reduce the burden of stroke in the patients we serve.

Publications